Heart Failure

Kazem Rahimi, MD: Home Monitoring for Cardiology Patients

September 28, 2020

Kazem Rahimi, MD, discusses the prospect of home monitoring for heart failure patients and how technology needs to improve before it is a viable option for most patients.

ESC Congress 2020 Hot Line Reviews

September 07, 2020

Dr. Gregory Weiss compiles thoughts and perspective on hot line trials presented at ESC Congress 2020.

Burkert Pieske, MD: Sacubitril/Valsartan for HFpEF

September 06, 2020

Lead investigator of the PARALLAX trial discusses whether he feels clinical data related to sacubitril/valsartan is strong enough to warrant prescribing it for HFpEF patients.

Milton Packer, MD: The Evolution of the SGLT2 Inhibitor Class

September 03, 2020

Milton Packer, MD, discusses how EMPEROR-Reduced data influences the way clinicians view the SGLT2 inhibitor class and its uses.

Dapagliflozin Proves Beneficial for CKD Patients With and Without Diabetes

August 30, 2020

Full results of the DAPA-CKD trial from ESC Congress 2020 detail the effects of dapagliflozin (Farxiga) among chronic kidney disease patients with and without type 2 diabetes.

PARALLAX Trial: Sacubitril/Valsartan Reduces NT-proBNP in HFpEF

August 30, 2020

Results of the PARALLAX trial shed light on the effects of sacubitril/valsartan (Entresto) in patients with heart failure with preserved ejection fraction.

Empagliflozin Effective for Heart Failure Patients, Regardless of Diabetes Status

August 29, 2020

Results of the phase 3 EMPEROR-Reduced trial indicate the SGLT2 inhibitor empagliflozin was effective for patients with HFrEF regardless of whether the patients had diabetes or not.

Analysis Details CV Risk Factors and Complications, Outcomes in 70k COVID-19 Patients

August 15, 2020

An analysis of more than 20 studies and 70k patients details the impact cardiovascular risk factors and complications can have on outcomes in patients hospitalized with COVID-19.

Testosterone, DHEA-S Levels Can Help Predict Heart Failure Development

August 14, 2020

New data suggests sex hormone levels could help predict development of heart failure in older men and postmenopausal women.

Loop Diuretic Use Improves 30-Day Outcomes Following Heart Failure Hospitalization

August 07, 2020

A new analysis of a Medicare-linked database is detailing associations between loop diuretic use and nonuse after heart failure hospitalization with 30-day clinical outcomes.